- Home
- LFS vs TIL Comparison
LFS vs TIL Comparison
Compare LFS & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LFS | TIL |
|---|---|---|
| Founded | 2001 | 2018 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.2M | 52.2M |
| IPO Year | 2024 | 2021 |
Fundamental Metrics
Financial Performance| Metric | LFS | TIL |
|---|---|---|
| Price | $2.25 | $5.70 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 88.1K | 28.0K |
| Earning Date | 10-07-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 6.06 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $25.19 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.58 | $5.62 |
| 52 Week High | $12.49 | $20.11 |
Technical Indicators
Market Signals| Indicator | LFS | TIL |
|---|---|---|
| Relative Strength Index (RSI) | 52.41 | 30.74 |
| Support Level | $2.11 | N/A |
| Resistance Level | $2.37 | $7.75 |
| Average True Range (ATR) | 0.14 | 0.38 |
| MACD | 0.01 | -0.07 |
| Stochastic Oscillator | 55.52 | 13.29 |
Price Performance
Historical ComparisonAbout LFS LEIFRAS Co. Ltd. American Depositary Shares
Leifras Co Ltd is a sports and social business company dedicated to youth sports and community engagement. It provide services related to the organization and operations of sports schools and sports events for children. The company focuses on covering 13 sports like soccer, basketball, and dance and in child athletic development, club activity management for schools, and social businesses like elderly care.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.